IMR Press / EJGO / Volume 22 / Issue 6 / pii/2001208

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma

Show Less
1 Department of Phannacology; Gynaecology and Obstetrics, University of Sassari, Italy
2 Institute of Pathology, University of Sassari, Italy
Eur. J. Gynaecol. Oncol. 2001, 22(6), 451–455;
Published: 10 December 2001

Objective: To assess the immunohistochemical expression of p53 protein, a tumour suppressor gene of the oncogene c-erb-B2 and MIB-1 proliferation marker (Ki-67 antigen) in endometrial carcinoma. Methods: We studied 29 cases of endometrial carcinoma in which the p53, c-erb-82 and MIB-l/Ki-67 antigens were investiga­ted by an immunohistochemical method. We evaluated the co订elations among the immunohistochemical positivity and the grading, depth of myometrial invasion, stage of the neoplasia and follow-up Results: Both p53 and c-erb-82 were positive in 16 out of 29 cases (55.2%), whereas MIB-1 was positive in 19 out of 29 cases (65.5%). All these three antigens showed a positive correlation with the grading, myometrial invasion and FIGO stage. Regarding follow-up, p53, c-erb-82 and MIB-1 were, respectively, positive in 100%, 83.4% and 66.7% of neoplasias of patients who died of disease whereas they were positive in 40%, 40% and 60%, respectively, of tumours of patients with no evidence of disease. Conclusion: The overexpression of p53, c-erb-B2 and MIB-1 seem to indicate a more malignant tumour phenotype.

Endometrial carcinoma
p53 tumour suppressor gene
MIB-1 proliferation marker (Ki-67 antigen)
Back to top